<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364984</url>
  </required_header>
  <id_info>
    <org_study_id>COVID20</org_study_id>
    <nct_id>NCT04364984</nct_id>
  </id_info>
  <brief_title>ARB, ACEi, DRi Effects on COVID-19 Course Disease</brief_title>
  <acronym>BIRCOV</acronym>
  <official_title>Effects of RAS Inhibitors (ARB, ACEi, DRI) in People With Hypertension 1-2 Stages on the Course of COVID-19 (BIRCOV Trial: ARB, ACEI, DRi Effects on COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Practice Prof D. Ivanov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Practice Prof D. Ivanov</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is supposed to monitor hypertensive patients who are infected or have clinical&#xD;
      manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be&#xD;
      considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      POEM (Patient-Oriented Evidence that Matters) intervention is performed as an open&#xD;
      prospective randomized two medical centres trial in subjects suffering from COVID-19 who have&#xD;
      been receiving iRAS, either ACEi, ARB or DRi as basic antihypertensive therapy.&#xD;
&#xD;
      COVID-19 is confirmed by a PCR test, the disease follow-up is divided into 2 periods: up to&#xD;
      12 weeks and up to 24 weeks.&#xD;
&#xD;
      Primary Outcome Measure: BP was known one week before COVID-19 and is tested during the&#xD;
      disease onset on weeks 2, 4, 12, 24. Secondary Outcome Measures are clinical features.&#xD;
      Subanalysis in patients with CKD is additionally performed for those who have CKD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 24, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Level of BP in mm Hg</measure>
    <time_frame>estimated at 2, 4, 12, 24 weeks after the start of COVID-19; data for 24 weeks are reported</time_frame>
    <description>BP in patients one week before COVID-19 infection and 2, 4, 12, 24 weeks follow-up after COVID-19 onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Fever Above 37.2 on COVID-19 Course</measure>
    <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
    <description>the number of patients with hypertension who received RASi and has a fever (above 37.2C) separately on 2, 4 and 12 weeks follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cough in COVID-19 Course</measure>
    <time_frame>on 2,4 and 12 week from COVID-19 onset</time_frame>
    <description>the absolute number of patients with hypertension on RASi who have had a cough at 2, 4 and 12 weeks from COVID-19 onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Throat Pain in COVID-19 Course</measure>
    <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
    <description>the number of patients with hypertension on RASi with throat pain at 2, 4 and 12 weeks follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Diarrhea Inf COVID-19 Course</measure>
    <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
    <description>the number of patients with hypertension on RASi with diarrhoea at 2, 4 and 12 weeks of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Need to Apply to Hospital in COVID-19 Course</measure>
    <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
    <description>the number of patients with hypertension on RASi who need hospital and intensive care unit at 2, 4 and 12 weeks of follow-up</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">112</enrollment>
  <condition>Hypertension</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ARB group</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received ARBs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEi group</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received ACEis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRi group</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin converting enzyme inhibitor</intervention_name>
    <description>routine drug intake</description>
    <arm_group_label>ACEi group</arm_group_label>
    <other_name>no other drug as RAS inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin Receptor Blockers</intervention_name>
    <description>routine drug intake</description>
    <arm_group_label>ARB group</arm_group_label>
    <other_name>no other drug as RAS inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Direct renin inhibitor</intervention_name>
    <description>routine drug intake</description>
    <arm_group_label>DRi group</arm_group_label>
    <other_name>no other drug as RAS inhibitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with proved COVID-19 and preliminary documented hypertension 1-2 stage on RASi at&#xD;
        the onset and COVID-19 course during 3 weeks&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hypertensive person, stage 1-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertensive subjects, stage 3, HF (NYHA) 3-4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iryna Navalna, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nephrology clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Practice Prof D.Ivanov</name>
      <address>
        <city>Kiev</city>
        <state>Please Select</state>
        <zip>01014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <results_first_submitted>August 27, 2021</results_first_submitted>
  <results_first_submitted_qc>February 16, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2022</results_first_posted>
  <last_update_submitted>February 16, 2022</last_update_submitted>
  <last_update_submitted_qc>February 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACEi, ARB, DRI</keyword>
  <keyword>Clinical features</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04364984/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>120 people with stage 1-2 hypertension have been screened. Study Population: patients with proved COVID-19 and preliminary stage 1-2 hypertension receiving iRAS at the onset of COVID-19.&#xD;
Minimum Age:18 Years, Maximum Age: 90 Years, Sex: All Inclusion Criteria: Hypertension, stage 1-2 with COVID-19. Exclusion Criteria: Hypertension, stage 3, HF (NYHA) 3-4</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: ARB Group</title>
          <description>44 patients with COVID-19, hypertension 1-2 stages, who received ARB as main therapy for hypertension</description>
        </group>
        <group group_id="P2">
          <title>Group 2: iACE Group</title>
          <description>44 patients with COVID-19 and hypertension 1-2 stages, who received iACE as the main treatment for hypertensions</description>
        </group>
        <group group_id="P3">
          <title>Group 3: DRI Group</title>
          <description>31 patients with COVID-19, hypertension 1-2 stages, who received ARB as main therapy for hypertension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARB Group</title>
          <description>Hypertensive patients with COVID-19 who received ARBs (valsartan 160-320 mg q.d. or olmesartan 20-40 mg q.d. or irbesartan 150-300 mg q.d. or candesartan 4-16 mg q.d.or losartan 50-100 mg q.d. in individual dosage) before and during COVID-19 for treatment of hypertension</description>
        </group>
        <group group_id="B2">
          <title>ACEi Group</title>
          <description>Hypertensive patients with COVID-19 who received ACEis (enalapril 10-20 mg q.d. or ramipril 5-10 mg q.d. or lisinopril 10-20 mg q.d. or perindopril 5-10 mg q.d. in individual regime) before and during COVID-19 for treatment of hypertension</description>
        </group>
        <group group_id="B3">
          <title>DRi Group</title>
          <description>Hypertensive patients with COVID-19 who received DRis (direct renin inhibitor rasilez in dosage 150-300 mg per day) before and during COVID-19 for treatment of hypertension</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>documents and records</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="1.8"/>
                    <measurement group_id="B2" value="55" spread="1.7"/>
                    <measurement group_id="B3" value="49" spread="1.4"/>
                    <measurement group_id="B4" value="55" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Level of BP in mm Hg</title>
        <description>BP in patients one week before COVID-19 infection and 2, 4, 12, 24 weeks follow-up after COVID-19 onset</description>
        <time_frame>estimated at 2, 4, 12, 24 weeks after the start of COVID-19; data for 24 weeks are reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Level of BP in mm Hg</title>
          <description>BP in patients one week before COVID-19 infection and 2, 4, 12, 24 weeks follow-up after COVID-19 onset</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="1.1"/>
                    <measurement group_id="O2" value="138" spread="1.1"/>
                    <measurement group_id="O3" value="34" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="1.2"/>
                    <measurement group_id="O2" value="83" spread="1.2"/>
                    <measurement group_id="O3" value="82" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Fever Above 37.2 on COVID-19 Course</title>
        <description>the number of patients with hypertension who received RASi and has a fever (above 37.2C) separately on 2, 4 and 12 weeks follow-up</description>
        <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
        <population>in the report, we document how many patients have a temperature above 37.2 on control data: 2, 4 and 12 weeks from COVID-19 onset</population>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Fever Above 37.2 on COVID-19 Course</title>
          <description>the number of patients with hypertension who received RASi and has a fever (above 37.2C) separately on 2, 4 and 12 weeks follow-up</description>
          <population>in the report, we document how many patients have a temperature above 37.2 on control data: 2, 4 and 12 weeks from COVID-19 onset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cough in COVID-19 Course</title>
        <description>the absolute number of patients with hypertension on RASi who have had a cough at 2, 4 and 12 weeks from COVID-19 onset</description>
        <time_frame>on 2,4 and 12 week from COVID-19 onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cough in COVID-19 Course</title>
          <description>the absolute number of patients with hypertension on RASi who have had a cough at 2, 4 and 12 weeks from COVID-19 onset</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Throat Pain in COVID-19 Course</title>
        <description>the number of patients with hypertension on RASi with throat pain at 2, 4 and 12 weeks follow-up</description>
        <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Throat Pain in COVID-19 Course</title>
          <description>the number of patients with hypertension on RASi with throat pain at 2, 4 and 12 weeks follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Diarrhea Inf COVID-19 Course</title>
        <description>the number of patients with hypertension on RASi with diarrhoea at 2, 4 and 12 weeks of follow-up</description>
        <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Diarrhea Inf COVID-19 Course</title>
          <description>the number of patients with hypertension on RASi with diarrhoea at 2, 4 and 12 weeks of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Need to Apply to Hospital in COVID-19 Course</title>
        <description>the number of patients with hypertension on RASi who need hospital and intensive care unit at 2, 4 and 12 weeks of follow-up</description>
        <time_frame>estimated at 2, 4, 12 weeks after the COVID-19 onset</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARB Group</title>
            <description>Hypertensive patients with COVID-19 who received ARBs</description>
          </group>
          <group group_id="O2">
            <title>ACEi Group</title>
            <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
          </group>
          <group group_id="O3">
            <title>DRi Group</title>
            <description>Hypertensive patients with COVID-19 who received DRis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Need to Apply to Hospital in COVID-19 Course</title>
          <description>the number of patients with hypertension on RASi who need hospital and intensive care unit at 2, 4 and 12 weeks of follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARB Group</title>
          <description>Hypertensive patients with COVID-19 who received ARBs</description>
        </group>
        <group group_id="E2">
          <title>ACEi Group</title>
          <description>Hypertensive patients with COVID-19 who received ACEis&#xD;
Angiotensin converting enzyme inhibitor: routine drug intake</description>
        </group>
        <group group_id="E3">
          <title>DRi Group</title>
          <description>Hypertensive patients with COVID-19 who received DRis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <description>hypotension as less than 110 mm Hg</description>
                <counts group_id="E1" events="35" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="42" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E3" events="31" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Dmytro Ivanov</name_or_title>
      <organization>Medical Practice Prof D.Ivanov</organization>
      <phone>0504448788 ext +38</phone>
      <email>drivanovdd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

